Antitumor reactivity in vitro and in vivo of lymphocytes from normal donors and cancer patients propagated in culture with T cell growth factor (TCGF)

Eli Kedar, Barbara L. Ikejiri, Tuomo Timonen, Guy D. Bonnard, James Reid, Nicanor J. Navarro, Benjamin Sredni, Ronald B. Herberman

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Peripheral blood lymphocytes (PBL) from 38 normal donors and from 27 cancer patients were propagated in bulk cultures for 3-6 weeks using T cell growth factor (TCGF). In addition, cultures derived from lymphocyte preparations enriched for or depleted of natural killer (NK) cells and several clones of cultured cells were studied. The following main observations were made: (a) PBL of both patients and healthy donors could be expanded to large numbers (up to 2500-fold); (b) CLC derived from unfractionated PBL exhibited intermediate levels of cytotoxic activity against autologous and allogeneic fresh lung tumor cells and strong cytotoxicity toward several cultured adherent tumor cells; (c) whereas cultures originated from populations enriched for NK cells were highly cytotoxic against both adherent tumor target cells and against an NK-sensitive leukemic cell line (K562), cultures derived from populations depleted of NK cells were preferentially cytotoxic to adherent target cells; (d) clones of CLC were also strongly cytotoxic, but 2 out of 3 clones tested showed a narrower spectrum of target cytotoxicity than that of uncloned CLC; (e) CLC, when mixed with two carcinoma cell lines, were able to inhibit tumor growth in nude mice.

Original languageEnglish
Pages (from-to)757-763,765-773
JournalEuropean Journal of Cancer and Clinical Oncology
Volume19
Issue number6
DOIs
StatePublished - Jun 1983
Externally publishedYes

Bibliographical note

Funding Information:
Accepted 14 January 1983. *Supported by a research grant given to the Lautenberg Center by the late Mr. Harold B. Abramson, New Jersey. Also supported in part by Naval Medical Research and Development Command, Research Task No. M0095-PN.OO1.0045 and an Interagency Agreement from the National Cancer Institute, No. YOl-CB-00319. The opinions and assertions contained herein are the private ones of the writers and are not to be confused as official or reflecting the views of the Navy Department or the naval service at large. The experiments reported herein were conducted according to the principles set forth in the current edition of the Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, National Research Council.

Funding

Accepted 14 January 1983. *Supported by a research grant given to the Lautenberg Center by the late Mr. Harold B. Abramson, New Jersey. Also supported in part by Naval Medical Research and Development Command, Research Task No. M0095-PN.OO1.0045 and an Interagency Agreement from the National Cancer Institute, No. YOl-CB-00319. The opinions and assertions contained herein are the private ones of the writers and are not to be confused as official or reflecting the views of the Navy Department or the naval service at large. The experiments reported herein were conducted according to the principles set forth in the current edition of the Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, National Research Council.

FundersFunder number
Naval Medical Research and Development Command

    Fingerprint

    Dive into the research topics of 'Antitumor reactivity in vitro and in vivo of lymphocytes from normal donors and cancer patients propagated in culture with T cell growth factor (TCGF)'. Together they form a unique fingerprint.

    Cite this